18 November 2022 - - US-based precision dermatology company DermTech, Inc. (NASDAQ: DMTK) has inked an agreement with Arizona, US-based diagnostic laboratory Sonora Quest Laboratories to expand access to enhanced melanoma detection, the company said.

As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network of healthcare providers.

The DermTech Melanoma Test uses a non-invasive Smart Sticker to lift skin cells from the surface of a patient's skin to be tested for select genomic markers associated with melanoma. It rules out melanoma with over 99% reliability.

The agreement between DermTech and Sonora Quest will increase the availability of the DermTech Melanoma Test to Arizonans through a visit to their healthcare providers within the Sonora Quest network.

Not only will this provide additional patient populations with heightened access to the DermTech Melanoma Test, but it could also reduce the number of unnecessary biopsies and referrals to specialists and reduce costs to the healthcare system.

One of the deadliest forms of skin cancer, melanoma is most treatable when diagnosed early in fact, the survival rate is 99% when detected early and only 27% once it spreads distantly.

Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics (NYSE: DGX), is one of the nation's largest integrated laboratory systems.

We are the trusted leader in diagnostic and information services with approximately 3,800 employees performing more than 97m diagnostic tests per year.

Our comprehensive test menu encompasses routine, molecular, prescription drug monitoring, genetic/genomic, women's health, and pathology testing services.

Sonora Quest is accredited by the College of American Pathologists, the gold standard in laboratory accreditation, which helps ensure the highest standard of care for laboratory operations.

DermTech is a genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform.

DermTech's mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care.

DermTech provides genomic analysis of skin samples collected non-invasively using its Smart Stickers.

DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments.